Activates AMPK, reducing hepatic gluconeogenesis by inhibiting PEPCK & G6Pase, & blocks mitochondrial complex I, boosting AMP levels and AMPK activity. Enhances muscle glucose uptake via GLUT4 & slightly decreases intestinal glucose absorption, lowering blood glucose without significant hypoglycemia. The gene discussed is SLC2A4; the disease is Hypoglycemia.